Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec 26;5(1):2.
doi: 10.3390/dj5010002.

Angiogenesis in the Development of Medication-Related Osteonecrosis of the Jaws: An Overview

Affiliations
Review

Angiogenesis in the Development of Medication-Related Osteonecrosis of the Jaws: An Overview

Andreas Max Pabst et al. Dent J (Basel). .

Abstract

Medication-related osteonecrosis of the jaws (MR-ONJ) is one of the most relevant side effects of bisphosphonate therapy; it is clinically defined as a non-healing wound in combination with an avascular and necrotic jaw within ongoing bisphosphonate therapy or after completed bisphosphonate therapy. Different theories concerning the development of MR-ONJ have been reported, while the exact pathophysiology is still unknown. Recent studies have increasingly focused on angiogenesis and revascularization concerning MR-ONJ pathophysiology, which seems to be a relevant factor in the development of MR-ONJ and a possible and promising point of action for MR-ONJ prevention and therapy. Therefore, and with respect to the different aspects and specific forms of angiogenesis, the enclosed review summarizes the possible role of angiogenesis and revascularization in the pathophysiology of MR-ONJ. Special focus is given to the strong negative influence of bisphosphonates on progenitor and mature endothelial cells in vitro as well as on microvessel sprouting in vitro and in vivo, which might result in overall reduced wound healing of oral soft and hard tissues, and therefore in an exposed and avascular jaw from a clinical viewpoint. Further, it will be summarized whether and in what way the aspect of angiogenesis might be used for possible MR-ONJ prevention and therapy.

Keywords: MR-ONJ; angiogenesis; bisphosphonate; endothelial cells; microvessel sprouting; osteonecrosis; progenitor cells; revascularization.

PubMed Disclaimer

Conflict of interest statement

None of the authors has any conflicts of interest.

Similar articles

Cited by

References

    1. Rogers M.J., Gordon S., Benford H.L., Coxon F.P., Luckman S.P., Monkkonen J., Frith J.C. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88:2961–2978. doi: 10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L. - DOI - PubMed
    1. Berenson J.R., Hillner B.E., Kyle R.A., Anderson K., Lipton A., Yee G.C., Biermann J.S. American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J. Clin. Oncol. 2002;20:3719–3736. doi: 10.1200/JCO.2002.06.037. - DOI - PubMed
    1. Pavlakis N., Schmidt R., Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst. Rev. 2005;3:CD003474. - PubMed
    1. Yuen K.K., Shelley M., Sze W.M., Wilt T., Mason M.D. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst. Rev. 2006;4:CD006250. - PubMed
    1. Kurth A.A., Heidenreich A., Diel I. Bisphosphonates in oncology. Orthopäde. 2007;36:131–135. doi: 10.1007/s00132-007-1051-1. - DOI - PubMed

LinkOut - more resources